Genetic anticancer therapy in which two genes are used for the treatment of colon cancer
The authors of this invention have developed a number of retroviral plasmids that incorporate the gef and apoptin genes, providing a pharmaceutical composition and a combination that can be employed in anticancer therapy, and specifically against colon cancer. These are also known as “suicide genes”, acting in the following manner:
- Gef, a prokaryotic gene that appears to act in a harmful way on cells via membrane modifications
- Apoptin, a gene codified by an avian virus, which induces apoptosis in the thymocytes of young birds under conditions of tissue growth.
These genes have been satisfactorily transfected, which has allowed the effects of their expression on the biological characteristics of the cancerous cells to be analysed.
The expression of the gef and apoptin genes, individually or combined, provokes morphological alterations that indicate the entry of specific cell populations in a process of programmed cell death, or apoptosis.
Licence agreement for operation and/or collaboration.
Sectors of application: Medicine, Molecular Biology.
Stage of development: International Patent requested.
Priority date: 26/07/2013. International Patent requested on 25/07/2014.
Owner: University of Granada, Andalusia Health Service and University of Jaén.